Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07376889 · ClinicalTrials.gov registry record · Phase 4
Combination Antibiotic Therapy for Staphylococcus Aureus Bacteremia
A Phase 4 study, sponsored by Intermountain Health Care.
- Not yet
- Registry status
- Phase 4
- Development phase
- 2,096
- Enrollment target
NCT07376889 is a Phase 4 study that has not yet begun recruiting, run by Intermountain Health Care. The registered enrollment target is 2,096 participants.
The verdict
NCT07376889, a Phase 4 study, has not yet begun recruiting, sponsored by Intermountain Health Care.
- NOT YET RECRUITING
- Registry status
- Phase 4
- Development phase
- 2,096 participants
- Enrollment target
Study Summary
The purpose of this study is to see if, in selected patients with a serious bacterial infection of the bloodstream, treating the bacterial infection with a combination of antibiotics is more effective than treating the infection with a single antibiotic. Participants must have blood cultures which are positive for a certain type of bacteria.
Interventions
- DRUG Antibiotic Monotherapy (AM) for patients with methicillin-sensitive S. aureus bacteremia (MSSAB)
- DRUG Antibiotic Monotherapy (AM) for patients with methicillin-resistant S. aureus bacteremia (MRSAB)
- DRUG Combination Antibiotic Therapy (CAT) for patients with methicillin-sensitive S. aureus bacteremia (MSSAB)
- DRUG Combination Antibiotic Therapy (CAT) for patients with methicillin-resistant S. aureus bacteremia (MRSAB)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,096 participants |
| Start Date | 2026-02-01 |
| Est. Completion | 2029-01 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07376889
The ClinicalTrials.gov registry entry for NCT07376889 describes a study currently listed as not yet recruiting, categorized as Phase 4. The registered enrollment target is 2,096 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Intermountain Health Care, which has 85 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Antibiotic Monotherapy (AM) for patients with methicillin-sensitive S. aureus bacteremia (MSSAB) is the first listed.
NCT07376889 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07376889 about?
NCT07376889 is a clinical study titled "Combination Antibiotic Therapy for Staphylococcus Aureus Bacteremia". The purpose of this study is to see if, in selected patients with a serious bacterial infection of the bloodstream, treating the bacterial infection with a combination of antibiotics is more effective than treating the infection with a single antibiotic. Participants must have blood cultures which a...
What is the current status of trial NCT07376889?
This trial is currently not yet recruiting. It is a Phase 4 study. The enrollment target is 2,096 participants. The study started on 2026-02-01. Estimated completion is 2029-01.
What interventions are being tested in trial NCT07376889?
The interventions under investigation include: Antibiotic Monotherapy (AM) for patients with methicillin-sensitive S. aureus bacteremia (MSSAB) (DRUG), Antibiotic Monotherapy (AM) for patients with methicillin-resistant S. aureus bacteremia (MRSAB) (DRUG), Combination Antibiotic Therapy (CAT) for patients with methicillin-sensitive S. aureus bacteremia (MSSAB) (DRUG), Combination Antibiotic Therapy (CAT) for patients with methicillin-resistant S. aureus bacteremia (MRSAB) (DRUG).
Who is sponsoring clinical trial NCT07376889?
This trial is sponsored by Intermountain Health Care, which has 85 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.